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OC-040 Nomogram for cumulative cisplatin dose for 
LAHNC receiving tri-weekly high-dose cisplatin CCRT 
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Purpose or Objective 
Tri-weekly high-dose cisplatin concurrent chemo-
radiotherapy (CCRT) is a standard regimen for locally 
advanced head and neck cancer (LAHNC) in both definitive 
and postoperative settings. However, this treatment 
causes severe acute toxicity in over three-quarters of 
patients. Consequently, many patients cannot tolerate 
high-dose cisplatin and receive lower cisplatin dose than 
expected, and thus have compromised outcome. 
Alternative treatment (weekly cisplatin or cetuximab) 
may be beneficial to these high-dose cisplatin-intolerant 
patients. Limited data identify the risk factors of high-
dose cisplatin intolerance. The goals of this study are to 
assess cisplatin tolerance, to identify the related risk 
factors, and to develop a nomogram for patient selection. 
Material and Methods 
Between 2010 and 2017, we retrospectively assessed 
consecutive patients who had received curative definitive 
CCRT with tri-weekly high dose cisplatin in a single 
tertiary institution. Patient characteristics (age, gender, 
performance score, Charlson Comorbidity Index (CCI), 
tumor site, stage, BMI, Hgb, albumin, eGFR, uric acid, 
neutrophil count, diabetes mellitus, hypertension, 
cirrhosis, smoking, alcohol consumption) were collected. 
Logistic regressions were performed for each factor to 
predict the cumulative cisplatin dose more than 200 
mg/m2 or not. A step-wise multivariate model was 
constructed to generate a nomogram. Model 
discrimination is evaluated using area under ROC curve 
(AUC) and Akaike Information Criterion (AIC). Overall 
survival was plotted with Kaplan-Meier method, stratified 
by cumulative cisplatin dose of 200 mg/m2. The survival 
results were compared by adjusted Cox regression. 
Results 
A total of 508 patients were assessed; 316, 69, 71, and 52 
patients had NPC, oropharyngeal cancer, hypopharyngeal 
cancer, and oral cavity cancer, respectively. The median 
follow-up time was 38.7 months. Three hundred and forty-
two (67.3%) patients had received cumulative cisplatin 
dose more than 200 mg/m2. Age, alcohol consumption, 
CCI, Hgb, and neutrophil count were significantly 
associated with cisplatin cumulative dose (Table 1). 
Incorporating these five factors, the nomogram (Fig. 1) 
achieved good concordance (AUC and AIC was 0.74, and 
756). A statistically significant association between 
cumulative cisplatin dose and survival was observed. 
 
Figure 1 
 
 
Table 1:Multi-variate logistic regression for cumulative 
cisplatin dose >= or < 200 mg/m2 
 OR 95% CI p value 
Alcohol (Yes vs No) 0.692 0.508-0.943 0.0198 
Hgb 1.306 1.208-1.414 <0.0001 
Neutrophil count 1.015 1.003-1.027 0.0152 
Age 0.961 0.946-0.976 <0.0001 
CCI 0.814 0.698-0.942 0.0069 
Conclusion 
The nomogram achieved an optimal prediction of 
cumulative cisplatin dose during CCRT in LAHNC. By 
applying this model, the risk of treatment intolerance can 
be determined, which can lead to better patient selection 
for tri-weekly high-dose cisplatin CCRT. 
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M. Saksoe1, K. Jensen2, M. Andersen3, J.G. Eriksen1, J. 
Overgaard1 
1Aarhus University Hospital, Dept. of Experimental 
Clinical Oncology, Aarhus, Denmark; 2Aarhus University 
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Purpose or Objective 
Despite encouraging results using primary radiotherapy 
(RT) for locally advanced head and neck squamous cell 
carcinoma (LAHNSCC), patients with p16-negative 
LAHNSCC continues to have a poor prognosis. This group 
has mostly tobacco- and alcohol-related cancer and 
consequently comorbidities which make treatment 
intensification challenging. The aim of this study was to 
assess the feasibility and efficacy of dose escalation using 
accelerated, hyperfractionated RT with nimorazole and 
weekly cisplatin in patients with p16-negative LAHNSCC 
and varying degrees of risk factors. 
Material and Methods 
Patients with increasing number of co-morbidities (as 
defined by the Charlson co-morbidity score) were 
allocated to primary accelerated hyperfractionated RT, 
76Gy/56fx, 10fx/week, concomitant weekly cisplatin 
(40mg/m2) and nimorazole according to the DAHANCA 
guidelines. The data analysis was performed as intention-
to-treat. Primary endpoint was loco-regional control. 
Secondary endpoints were overall survival and toxicity. No 
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elective neck dissections were allowed. With respect to 
dose coverage, spatial analyses of failure sites were made 
for patients with residual or recurrent disease. 
Results 
From February 2013 to November 2015, 31 patients were 
accrued. The median age was 61 years and 77% were 
males. All had WHO performance 0 (65%) or 1 (35%), most 
were current smokers (81%, median 41 pack years) and 
had increasing co-morbidity scores from 0 to 2. All had 
p16-negative, LAHNSCC; mostly stage IV (90%) pharynx 
carcinomas (74%). The proportion of patients receiving RT 
as planned was 94%, whereas compliance to full treatment 
with cisplatin and nimorazole was lower, 58% and 74%, 
respectively. Nine loco-regional recurrences were 
detected with a median follow-up time of 27 months 
(range 0-61), and two of these were in patients, who 
terminated treatment prematurely. A pattern-of-failure 
analysis by co-registering planning and recurrence CT 
showed that all loco-regional recurrences were in the high 
dose CTV. One patient presented with distant metastases 
only. The three-year actuarial loco-regional tumor control 
was 70%, whereas overall survival was 58%. Almost 80% 
needed tube-feeding during treatment, but at two months 
after end of therapy, this was reduced to 50% and at 6 
months to 17%. At end of therapy, 20% experienced 
grade≥3 dysphagia and 15% grade≥3 mucositis. The 
proportion of patients reporting severe late dysphagia was 
16% and 42% reported late, moderate to severe dryness of 
the mouth.  
Conclusion 
Accelerated hyperfractionated RT with concomitant low-
dose cisplatin and nimorazole is feasible in patients with 
locally advanced p16-negative head and neck squamous 
cell carcinoma presenting in good general 
health.  Outcome in terms of loco-regional tumor control 
at 3 years is encouraging with an anticipated and 
acceptable level of acute and late toxicity. 
 
OC-042 Genomic characterization of oral premalignant 
lesions to identify high-risk molecular clusters 
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Purpose or Objective 
Oral premalignant lesions (OPLs) represent the most 
common oral precancerous conditions. One of the major 
challenges in this field is the identification of OPLs at 
higher risk for oral squamous cell cancer (OSCC) 
development, possibly revealing molecular pathways to be 
regulated before their malignant transformation.  
Gene expression analysis represents a useful tool to 
evaluate genomic pathways of OPLs with such a clinical 
implication.  
We aimed at dissecting genomic characteristics of OPLs to 
identify high-risk molecular clusters. 
Material and Methods 
By an unsupervised clustering analysis, we previously 
disclosed 6 molecular subtypes in a large meta-analysis 
comprising 1386 head and neck SCC cases (De Cecco et al, 
2015).  
We investigated whether these molecular patterns were 
already present in OPLs, by applying this model to a gene-
expression data set of patients enrolled in a clinical 
chemoprevention trial, which employed malignant 
transformation as the primary endpoint (Saintigny et al, 
2011).  
Gene expression profile was measured in 86 of 162 OPL 
patients. These cases were then stratified accordingly to 
our subtype classification applying the PAM signature 
including 2843 genes. 
Results 
Overall, 2 cases (2.3%) were classified as Cluster (Cl) 1-
HPV, 10 (11.6%) as Cl2-Mesenchymal, 11 (12.8%) as Cl3-
Hypoxia, 21 (24.4%) as Cl4-Defense Response, 11 (12.8%) 
as Cl5-Classical, and 31 (36%) as Cl6-Immunoreactive.  
This molecular stratification was then correlated with oral 
cancer-free survival as calculated by Kaplan-Meyer 
analysis.  
Patients stratified as Cl3-Hypoxia and Cl5-Classical 
showed the worst clinical behaviors, with a higher risk of 
malignant transformation (log rank, p=0.0052). 
Conclusion 
Dissecting the pathways of OPLs by evaluation of the 
different clusters obtained with gene expression profiling, 
we identified 2 clusters at higher risk of oral cancer 
development, namely Hypoxia and Classical clusters.  
Further researches are needed to improve the 
identification of adequate prognosticators in OPLs and to 
find molecular pathways to be addressed for reduction of 
the risk of cancerization. 
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Purpose or Objective 
Hafnium oxide nanoparticles, NBTXR3, were developed to 
augment tumor-localized high energy deposit once 
activated by ionizing radiation such as Intensity Modulated 
Radiation Therapy (IMRT) and thus to increase tumor cell 
death compared to the same dose of radiation. NBTXR3 is 
characterized by a single intratumoral (IT) administration 
and fits into standard radiotherapy schedule with no 
change in patient’s care pathway, treatment protocol or 
equipment. A phase I trial is currently evaluating NBTXR3 
in elderly patients (pts) with locally advanced head and 
neck squamous cell carcinoma (HNSCC) of the oral cavity 
and oropharynx not eligible for cisplatin or intolerant to 
cetuximab [NCT01946867]. 
Material and Methods 
In this phase I open-label, non-randomized trial, elderly 
frail pts (65 years and older) were treated with an IT 
injection of NBTXR3 followed by IMRT (70 Gy in 35 
fractions over 7 weeks) with a follow-up period until 
disease progression or study cut-off date. The study was 
designed as a 3 + 3 escalation dose with tested NBTXR3 
